AU2007316589B2 - Use of tri-substituted glycerol compounds for the treatment of radiation injuries - Google Patents

Use of tri-substituted glycerol compounds for the treatment of radiation injuries Download PDF

Info

Publication number
AU2007316589B2
AU2007316589B2 AU2007316589A AU2007316589A AU2007316589B2 AU 2007316589 B2 AU2007316589 B2 AU 2007316589B2 AU 2007316589 A AU2007316589 A AU 2007316589A AU 2007316589 A AU2007316589 A AU 2007316589A AU 2007316589 B2 AU2007316589 B2 AU 2007316589B2
Authority
AU
Australia
Prior art keywords
radiation
medicament
cells
injury
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007316589A
Other languages
English (en)
Other versions
AU2007316589A1 (en
Inventor
Wolfgang Richter
Lutz Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radioprotect Alphaptose Ug (haftungsbeschraenkt) & Co KG
Original Assignee
Radioprotect Alphaptose Ug Haftungsbeschraenkt & Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radioprotect Alphaptose Ug Haftungsbeschraenkt & Co KG filed Critical Radioprotect Alphaptose Ug Haftungsbeschraenkt & Co KG
Publication of AU2007316589A1 publication Critical patent/AU2007316589A1/en
Assigned to RADIOPROTECT ALPHAPTOSE UG (HAFTUNGSBESCHRANKT) & CO. KG reassignment RADIOPROTECT ALPHAPTOSE UG (HAFTUNGSBESCHRANKT) & CO. KG Alteration of Name(s) of Applicant(s) under S113 Assignors: ALPHAPTOSE GMBH
Assigned to RadioProtect Alphatose UG (haftungsbeschraenkt) & Co. KG reassignment RadioProtect Alphatose UG (haftungsbeschraenkt) & Co. KG Request for Assignment Assignors: RADIOPROTECT ALPHAPTOSE UG (HAFTUNGSBESCHRANKT) & CO. KG
Application granted granted Critical
Publication of AU2007316589B2 publication Critical patent/AU2007316589B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2007316589A 2006-11-10 2007-11-09 Use of tri-substituted glycerol compounds for the treatment of radiation injuries Ceased AU2007316589B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85817006P 2006-11-10 2006-11-10
US60/858,170 2006-11-10
PCT/EP2007/062181 WO2008055997A1 (en) 2006-11-10 2007-11-09 Use of tri-substituted glycerol compounds for the treatment of radiation injuries

Publications (2)

Publication Number Publication Date
AU2007316589A1 AU2007316589A1 (en) 2008-05-15
AU2007316589B2 true AU2007316589B2 (en) 2013-03-07

Family

ID=38904569

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007316589A Ceased AU2007316589B2 (en) 2006-11-10 2007-11-09 Use of tri-substituted glycerol compounds for the treatment of radiation injuries

Country Status (9)

Country Link
US (1) US20100130449A1 (OSRAM)
EP (1) EP2089401B1 (OSRAM)
JP (2) JP5512275B2 (OSRAM)
AU (1) AU2007316589B2 (OSRAM)
CA (1) CA2668923C (OSRAM)
DK (1) DK2089401T3 (OSRAM)
ES (1) ES2391659T3 (OSRAM)
RU (1) RU2448973C2 (OSRAM)
WO (1) WO2008055997A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2668923C (en) * 2006-11-10 2015-01-13 Alphaptose Gmbh Use of tri-substituted glycerol compounds for the treatment of radiation injuries
JP6411725B2 (ja) 2013-10-31 2018-10-24 株式会社Ｎｔｔドコモ 無線基地局、ユーザ端末および無線通信方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266564A (en) * 1989-06-02 1993-11-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Method for treating certain autoimmune diseases
US6514519B1 (en) * 1998-05-19 2003-02-04 Med-Mark Pharma Gmbh Edelfosin for the treatment of brain tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5082846A (en) * 1990-08-30 1992-01-21 Sandoz Ltd. Use of the R-(+)-isomer of 2-methoxy-3-octadecyloxy-propanol-(1)-phosphoric acid, monocholine ester in treating multiple sclerosis
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
SE517142C2 (sv) * 2000-04-11 2002-04-23 Delaval Holding Ab Utfodringsanordning samt arrangemang och förfarande för automatisk mjölkutfodring
WO2005020935A2 (en) * 2003-02-06 2005-03-10 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Method and composition of administering radioprotectants
CA2668923C (en) * 2006-11-10 2015-01-13 Alphaptose Gmbh Use of tri-substituted glycerol compounds for the treatment of radiation injuries

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266564A (en) * 1989-06-02 1993-11-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Method for treating certain autoimmune diseases
US6514519B1 (en) * 1998-05-19 2003-02-04 Med-Mark Pharma Gmbh Edelfosin for the treatment of brain tumors

Also Published As

Publication number Publication date
JP2013227341A (ja) 2013-11-07
US20100130449A1 (en) 2010-05-27
JP2010509294A (ja) 2010-03-25
JP5512275B2 (ja) 2014-06-04
RU2009121836A (ru) 2010-12-20
DK2089401T3 (da) 2012-09-17
AU2007316589A1 (en) 2008-05-15
EP2089401A1 (en) 2009-08-19
WO2008055997A1 (en) 2008-05-15
ES2391659T3 (es) 2012-11-28
CA2668923C (en) 2015-01-13
CA2668923A1 (en) 2008-05-15
EP2089401B1 (en) 2012-07-25
RU2448973C2 (ru) 2012-04-27

Similar Documents

Publication Publication Date Title
Masuda et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Santini Amifostine: chemotherapeutic and radiotherapeutic protective effects
AU627207B2 (en) Pharmaceutical composition comprising protein kinase c inhibitor and anti-cancer agent
US20100190738A1 (en) Use of Aalkylphophocholines in Combination with Antitumor Medication for the Treatment of Benign and Melignant Oncoses in Humans and Mammals
US6063814A (en) Phorbol esters as anti-neoplastic and white blood cell elevating agents
US5488042A (en) Method for protection against genotoxic mutagenesis
Carnes et al. In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis
CA2668923C (en) Use of tri-substituted glycerol compounds for the treatment of radiation injuries
EP4230205B1 (en) Polyethylene glycol-modified irinotecan and temozolomide compositions
AU2008240118B2 (en) Methods for treating neoplasia with combination of chemotherapeutic agents and radiation
Gundersen et al. Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease
JP2006510714A (ja) 放射線被爆患者の処置方法
CA2673040C (en) Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
Gastaut et al. Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG)
Kumar et al. Perspectives in radiological and nuclear countermeasures
Bhartiya et al. Effects of S-2 (3-aminopropylamino) ethylphosphorothioic acid (WR-2721) on the sensitivity of mouse spermatogonia A to radiation
AU2023356925A1 (en) Improved treatment of cancers using combinations of SMARCA2 degraders and KRAS targeting therapies
CA3268732A1 (en) Improved treatment of cancers using combinations of smarca2 degraders and kras targeting therapies
Dietz et al. Complications after combination of chemotherapy and radiation for malignant brain tumours
CA2436332A1 (en) Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
AU2011204918A1 (en) Use of alkylphosphocholines in combination with antitumor medicaments
JP2010184936A (ja) 放射線被爆患者の処置方法
JPH08291064A (ja) 殺癌細胞剤
HK1152247A1 (en) Methods of treatment employing prolonged continuous infusion of belinostat
HK1152247B (en) Methods of treatment employing prolonged continuous infusion of belinostat

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RADIOPROTECT ALPHATOSE UG (HAFTUNGSBESCHRAENKT) &

Free format text: FORMER APPLICANT(S): RADIOPROTECT ALPHAPTOSE UG (HAFTUNGSBESCHRANKT) & CO. KG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired